Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney
cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and …

The incidence of renal cell carcinoma (RCC) is rising and metastatic RCC carries a very
poor prognosis. The treatment paradigm for metastatic RCC has shifted dramatically in the …

Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Background Few treatment options are available for patients with advanced renal cell
carcinoma who have received previous anti-PD-1-based or anti-PD-L1-based …

Background Stereotactic ablative body radiotherapy (SABR) is an option for oligometastatic
clear cell renal cell carcinoma (ccRCC) but is limited by a lack of prospective clinical trial …

Background Immunotherapy-based combinations including pembrolizumab plus lenvatinib
are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these …

Background Results from the phase 3 CLEAR study showed that lenvatinib plus
pembrolizumab improved progression-free survival and overall survival compared with …

PURPOSE To determine the value of tumor cell programmed death-ligand 1 (PD-L1)
expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive …

Understanding the protection conferred by previous infection against repeat infection,
illness, and severe disease is key to projecting the future epidemiology of COVID-19 and to …